Moreover, cancers with CDK12 mutations are often sensitive to PARP inhibitors - and preclinical and biological data from patients with PCa showed that CDK12 inactivation is related to increased burden of neoantigens, which can in turn enhance the immunogenicity (84). The gene discussed is CDK12; the disease is cancer.